The various generic players has got approval to market Mycophenolate Moefetil (Cellcept) 250 mg capsules and 500 mg tablets after Mycophenolate's product patent US4753935 expired on May 3, 2009.
Following generic players have got final approval to market this drug from USFDA:
1. SANDOZ
2. ROXANE
3. ACCORD HEALTHCARE
4. ZYDUS PHARMS
5. TEVA PHARMS
6. MYLAN
7. APOTEX
Earlier, innovator ROCHE PALO got approval to market Mycophenolate Moefetil tablets on June 19, 1997 and Mycophenolate Moefetil capsules on May 3, 1995.
As per IMS health, U.S. sales of Mycophenolate Moefetil are approximately $680 million for tablets and $367 million for capsules, respectively, for the 12 months ending March 31, 2009.
Mycophenolate is used for the prevention of organ transplant rejection and acts as an immunosuppressant.
Earlier news of IP Pharm Doc on this product Here
No comments:
Post a Comment